Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomes

• প্রধান লেখক: Katalin Pungor (লেখক), Vasilis P. Bozikas (লেখক), Robin Emsley (লেখক), Pierre-Michel Llorca (লেখক), Srihari Gopal (লেখক), Maju Mathews (লেখক), Annette Wooller (লেখক), Paul Bergmans (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: SAGE Publishing, 2020-12-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

Background: Paliperidone palmitate 3-monthly (PP3M) is a second-generation, long-acting injectable antipsychotic formulation indicated for the maintenance treatment of adults with schizophrenia first stabilized with paliperidone palmitate 1-monthly (PP1M). This exploratory post hoc subgroup analysis...